Premium
Interleukin‐33: a novel mediator with a role in distinct disease pathologies
Author(s) -
KurowskaStolarska M.,
Hueber A.,
Stolarski B.,
McInnes I. B.
Publication year - 2011
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.2010.02316.x
Subject(s) - mediator , medicine , cytokine , immunology , interleukin 33 , inflammation , disease , pathophysiology , immune system , interleukin , interleukin 6 , bioinformatics , pathology , biology
Kurowska‐Stolarska M, Hueber A, Stolarski B, McInnes IB (Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK). IL‐33 – a novel mediator with a role in distinct disease pathologies (Key Symposium). J Intern Med 2011; 269 : 29–35. Abstract. Interleukin‐33 (IL‐33) is a novel member of IL‐1 cytokine family. It can act both as a nuclear factor and as a soluble mediator; however, the precise role of IL‐33 within the nucleus is still not clear. As a cytokine, IL‐33 is suggested to function as an alarmin that is released upon endothelial or epithelial cell damage. As such, IL‐33 targets multiple cell types thereby alerting the immune system to endogenous trauma such as physical stress or infection. However, a dysregulated release of IL‐33 has a potential to drive distinct pathologies. In this review, we discuss the contribution of IL‐33 to the pathophysiology of asthma, arthritis, obesity and atherosclerosis as well as the potential of IL‐33 for therapeutic intervention.